Topic: shareholder activism
A senior member of the founding Takeda family spoke out against the Shire deal for the first time, calling it a betrayal of company culture.
More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.
Ironwood may have avoided sparring with activists by introducing an R&D split-off, but its employees paid the price.
Allergan is in the middle of making some moves to revive its struggling shares. And the success of its pipeline could dictate its next moves, analysts say.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
Some Allergan shareholders reportedly have a former insider in mind for the chairman's role: David Pyott, who led the company until its buyout in 2015.
Takeda shareholders who oppose the company’s $62 billion buyout of Shire are gaining support for their effort to block the deal.
Just as rebel investors are calling for a C-suite shakeup at Allergan, activist Carl Icahn has reportedly jumped in.
Investors are so unhappy after Allergan's strategic review that they're calling for a C-suite shakeup—and that could mean a new CEO.
Ironwood’s activist investor likes what it’s seen recently from the drugmaker—so much so that it held off on pushing for a spot on the company's board.